Drug intelligence / Profile preview

D-leucyl-N-(3-chlorobenzyl)-L-prolinamide

Development stage: Preclinical
Modality: Small Molecules, Peptides

Overview

D-leucyl-N-(3-chlorobenzyl)-L-prolinamide is a synthetic dipeptide derivative composed of D-leucine and L-proline, with a 3-chlorobenzyl group attached to the nitrogen atom of the proline residue. It is classified as a small molecule and has been investigated primarily as an experimental compound. Its main mechanism of action is inhibition of prothrombin, suggesting potential anticoagulant or antithrombotic activity. The compound has not been approved for any indication and remains at the investigative stage, with no clinical trials reported beyond preclinical research[1][2][8].

Other names: N-(3-Chlorobenzyl)-1-[(2R)-2-amino-4-methylpentanoyl]-L-prolinamide(2S)-1-[(2R)-2-amino-4-methylpentanoyl]-N-[(3-chlorophenyl)methyl]pyrrolidine-2-carboxamide

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on D-leucyl-N-(3-chlorobenzyl)-L-prolinamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-leucyl-N-(3-chlorobenzyl)-L-prolinamide.